Prevalence and genotypic distribution of high-risk human papilloma virus in Gomel region: Screening results of 11,382 women over 2018–2023

INTRODUCTION. High-risk human papillomavirus (hrHPV) is a proven etiological factor in prevalence of cervical cancer. Screening with HPV genotyping in women and identifying significant regional virus genotypes is vital for implementation of HPV immunisation programmes.

AIM. This study aimed to examine the prevalence, spectrum, and regional characteristics of hrHPV in women from different districts of Gomel region in 2018–2023, prior to the mass vaccination programme in the Republic of Belarus.

MATERIALS AND METHODS. A total of 11,382 women from Gomel region and the city of Gomel aged 18 to 79 years were examined in 2018–2023. Biomaterial samples (endocervical scrapings) were taken from each study participant for subsequent molecular genetic analysis using polymerase chain reaction.

RESULTS. A total of 14 different HPV genotypes have been detected. The incidence of hrHPV was 9% in the overall population and 9.7% in women of reproductive age. High hrHPV incidence was noted in women of early reproductive age: group of 18–24 years — 18.8% (95% CI 16.8–20.9), 25–29 years — 12.1% (95% CI 10.3–14.1), and 30–34 years — 9.2% (95% CI 7.8–10.7). A single HPV genotype was detected most frequently (78.6%); a combination of two HPV genotypes was detected in 86 patients (14.5%); ≥3 genotypes — in 41 patients (6.9%). The most common genotypes were 16 (52.2%), 18 (15.1%), 51 (18.9%), 56 (9.8%), and 31 (9.7%) HPV. Groups α9 (16 and 31 genotypes), α7 (18 genotype), α5 (51 genotype), and α6 (56 genotype) most frequently caused hrHPV infection in women. A change has been found in the structure of dominant hrHPV genotypes in Gomel region over the past 10 years.

CONCLUSION. A high hrHPV prevalence has been established among women of reproductive age in Gomel region. Data on HPV genomic diversity in the region are essential for molecular epidemiological surveillance and will help assess the effectiveness of the Republican HPV immunisation programme launched in 2025.

1. Reuschenbach M, Valente S, Takyar J, et al. Treatment characteristics, HPV genotype distribution and risk of subsequent disease among women with high-grade cervical intraepithelial neoplasia in Europe: A systematic literature review. Eur J Obstet Gynecol Reprod Biol. 2024;300:129–40. https://doi.org/10.1016/j.ejogrb.2024.06.030

2. Wang X, Huang X, Zhang Y. Involvement of human papillomaviruses in cervical cancer. Front Microbiol. 2018;9:2896. https://doi.org/10.3389/fmicb.2018.02896

3. Correa RM, Baena A, Valls J, et al. Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America. PLoS One. 2022;17(7):e0272205. https://doi.org/10.1371/journal.pone.0272205

4. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1–441. PMID: 23189750

5. Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol. 2014;234(4):431–5. https://doi.org/10.1002/path.4424

6. Burd EM. Human papillomavirus laboratory testing: the changing paradigm. Clin Microbiol Rev. 2016;29(2):291–319. https://doi.org/10.1128/CMR.00013-15

7. Chen Z, Schiffman M, Herrero R, et al. Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61). Virology. 2018;516:86–101. https://doi.org/10.1016/j.virol.2018.01.002

8. Baba SK, Alblooshi SSE, Yaqoob R, et al. Human papilloma virus (HPV) mediated cancers: an insightful update. J Transl Med. 2025;23:483. https://doi.org/10.1186/s12967-025-06470-x

9. Obeid DA, Almatrrouk SA, Alfageeh MB, et al. Human papillomavirus epidemiology in populations with normal or abnormal cervical cytology or cervical cancer in the Middle East and North Africa: A systematic review and meta-analysis. J Infect Public Health. 2020;13(9):1304–13. https://doi.org/10.1016/j.jiph.2020.06.012

10. Chemaitelly H, Finan RR, Racoubian E, et al. Estimates of the incidence, prevalence, and factors associated with common sexually transmitted infections among Lebanese women. PLoS ONE. 2024;19(4):e0301231. https://doi.org/10.1371/journal.pone.0301231

11. Han S, LinM, LiuM, et al. Prevalence, trends, and geographic distribution of human papillomavirus infection in Chinese women: a summative analysis of 2,728,321 cases. BMC Med. 2025;23:158. https://doi.org/10.1186/s12916-025-03975-6

12. Okoye JO, Chukwukelu CF, Okekpa SI, et al. Racial disparities associated with the prevalence of vaccine and non-vaccine HPV types and multiple HPV infections between Asia and Africa: A systematic review and meta-analysis. Asian Pac J Cancer Prev. 2021;22(9):2729–41. https://doi.org/10.31557/APJCP.2021.22.9.2729

13. Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus prevalence in 5 continents: Meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99. https://doi.org/10.1086/657321

14. Osmani V, Hörner L, Nkurunziza T, et al. Global prevalence of cervical human papillomavirus in women aged 50 years and older with normal cytology: a systematic review and meta-analysis. Lancet Microbe. 2025;6(1):100955. https://doi.org/10.1016/j.lanmic.2024.100955

15. Berza N, Zodzika J, Kivite-Urtane A, et al. Understanding the high-risk human papillomavirus prevalence and associated factors in the European country with a high incidence of cervical cancer. Eur J Public Health. 2024;4(34):826–32. https://doi.org/10.1093/eurpub/ckae075

16. Baranov AA, Plakida AV, Namazova-Baranova LS, et al. Analysis of the economic and socio-demographic burden of HPV-associated diseases and the cost-effectiveness of HPV vaccination in Russia. Pediatric pharmacology. 2019;16(2):101–10 (In Russ.). https://doi.org/10.15690/pf.v16i2.2007

17. Beliakouski VN, Voropaev EV. Human papillomavirus infection and cervical cancer. Health and Ecology Issues. 2006;(4):18–23 (In Russ.). https://doi.org/10.51523/2708-6011.2006-3-4-3

18. Volchenko AN. Genotyping of papillomavirus infection of high carcinogenic risk. In: Youth in Science — 2011: Proceedings of the International Scientific Conference of Young Scientists, Minsk, April 25–29, 2011: Supplement to the journal “Proceedings of the National Academy of Sciences of Belarus, Biological and Medical Series”. Part 3. Minsk: Belarusian Science; 2012. P. 241–6 (In Russ.).

19. Na J, Li Y, Wang J, et al. The correlation between multiple HPV infections and the occurrence, development, and prognosis of cervical cancer. Front Microbiol. 2023;14:1220522. https://doi.org/10.3389/fmicb.2023.1220522

20. Wu P, Xiong H, Yang M, et al. Co-infections of HPV16/18 with other high-risk HPV types and the risk of cervical carcinogenesis: A large population-based study. Gynecol Oncol. 2019;155(3):436–43. https://doi.org/10.1016/j.ygyno.2019.10.003

21. Turanova OV, Belokrinitskaya TE, Belozertseva EP, Avrachenkova AV. HPV infection: prospective observation of elimination and assessment of risk factors for persistence. Doctor.Ru. 2019;4(159):31–5 (In Russ.). https://doi.org/10.31550/1727-2378-2019-159-4-31-35

22. Auvray C, Douvier S, Caritey O, et al. Relative distribution of HPV genotypes in histological cervical samples and associated grade lesion in a women population over the last 16 years in Burgundy, France. Front Med (Lausanne). 2023;10:1224400. https://doi.org/10.3389/fmed.2023.1224400

23. Rositch AF, Gravitt PE, Smith JS. Growing evidence that HPV infection is associated with an increase in HIV acquisition: exploring the issue of HPV vaccination. Sex Transm Infect. 2013;89(5):357. https://doi.org/10.1136/sextrans-2012-050870

24. Zhao M, Zhou D, Zhang M, et al. Characteristic of persistent human papillomavirus infection in women worldwide: a meta-analysis. PeerJ. 2023;11:e16247. https://doi.org/10.7717/peerj.16247

25. Brown DR, Joura EA, Yen GP, et al. Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence. Vaccine. 2021;39(16):2224–36. https://doi.org/10.1016/j.vaccine.2020.11.076